-
Emmys gala will now stream its premier television awards
-
Ronaldo opens door for Portugal return, apologises for walkout
-
Paramount completes Warner Bros takeover, creating Skydance
-
'Nobody seems to care': Russian city shrugs off plague reports
-
Trump blames France unrest on Islam, migration
-
Hundreds arrested in French school protests as Macron summons ministers
-
Apple's Cook praises EU over efforts to protect children online
-
WADA seeks tough anti-doping stance from Kenya
-
Nobel winner Halzen says years of October 'misery' finally over
-
German ex-spy chief arrested for suspected espionage, treason
-
Quebec separatist win rattles Carney's unity push
-
Furyk vows US will 'do more' to end Ryder Cup losing streak
-
'Itching' for change: Shiffrin cuts back slaloms this season
-
Iyer hits ton as India hammer West Indies in T20 opener
-
'Gen Z has risen up': Tens of thousands mass for tense France school protests
-
Mandhana named India women's team captain after Kaur quits
-
Caribbean tourism hotspot loses men to Russian war machine
-
'The sound keeps coming back': children maimed in Ethiopia's Tigray clashes
-
Danish reservists practice war games to respond to 'aggression'
-
Paris Women's Fashion Week: the key trends
-
Bhuvneshwar returns to India's T20 squad for New Zealand tour
-
i-payout Introduces a New Approach to Payments, Closing the Beneficiary Information Gap
-
Asos says probing 'unauthorised activity' after phone alerts
-
New Generation of Crypto Miners Released by ASICID
-
Stocks climb as oil prices retreat under $100 per barrel
-
New investor forecasts LIV Golf teams could be worth $100 mn each
-
Neutrinos: space particles that change our view of universe
-
Shakira, Pique return to court over children visit arrangements
-
'Destined' Djokovic wins China Open, extending unbeaten record
-
Nobel physics prize hails 'ghostly messengers' from space
-
Iceland is 'critical outpost' for security, says Rubio during visit
-
France's Mistral unveils latest model in sovereign AI push
-
Israeli settlers beat AFP photographer covering West Bank
-
Stocks climb as oil prices retreat
-
'Gen Z has risen up': Tens of thousands demand better education in France
-
Vstock Transfer Names Securities Industry Veteran Erica Goodstein General Counsel and Chief Compliance Officer
-
$10 Million and Counting: Hola Prime Hits Major Trader Payout Milestone
-
Four Indonesian seamen return home after Somali pirate ordeal
-
UEFA investigate Ireland-Israel tunnel bustup after spitting claim
-
Crisis-striken Haiti postpones elections
-
Djokovic wins China Open and keeps unbeaten record after de Minaur retires
-
Germany arrests ex-spy chief on suspicion of giving secrets to foreign powers
-
Amsterdam's Rijksmuseum hosts 'homecoming' show for Willem de Kooning
-
Djokovic wins China Open after de Minaur retires
-
World Bank forecasts modest growth for Latin America, highlights climate risks
-
IMF warns cost-of-living shocks cause 'lasting deterioration' in affordability
-
'Afraid for my future': Tens of thousands demand better education in France
-
Alcaraz wins Japan Open for first title since injury return
-
Pakistan PM urges Imran Khan supporters to end protest march
-
'We're working to keep football clean', Turkish minister says
Revive Therapeutics Announces Proposed Shares for Debt Settlement
TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, announces a proposed debt settlement pursuant to which the Company intends to issue up to 1,221,516 common shares in the capital of the Company (the "Settlement Shares") at a deemed price of $0.05 per Settlement Share to settle an aggregate of $61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement").
The Settlement Shares will be issued in accordance with the policies of the Canadian Securities Exchange (the "CSE"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws. Completion of the Debt Settlement remains subject to certain conditions, including receipt of all necessary regulatory approvals, including approval of the CSE.
The Debt Settlement is expected to close no earlier than five business days from the date of this news release and remains subject to CSE acceptance
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1-888-901-0036
Email: [email protected]
Website: www.revivethera.com
SOURCE: Revive Therapeutics Ltd.
View the original press release on ACCESS Newswire
E.Hall--AT